Advisor Group Holdings, Inc. Cellectis S.A. Transaction History

Advisor Group Holdings, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.41 - $3.09 $8,435 - $10,815	-3,500 Reduced 76.42%	1,080 $2,000
Q4 2023 Feb 12, 2024	SELL	$0.97 - $3.55 $4,258 - $15,584	-4,390 Reduced 48.94%	4,580 $14,000
Q3 2023 Nov 13, 2023	BUY	$1.58 - $2.86 $5,695 - $10,310	3,605 Added 67.19%	8,970 $14,000
Q2 2023 Aug 10, 2023	SELL	$1.72 - $2.12 $1,453 - $1,791	-845 Reduced 13.61%	5,365 $10,000
Q1 2023 May 12, 2023	SELL	$1.83 - $3.84 $49 - $103	-27 Reduced 0.43%	6,210 $11,000
Q4 2022 Feb 10, 2023	SELL	$1.85 - $2.6 $307 - $431	-166 Reduced 2.59%	6,237 $13,000
Q3 2022 Nov 14, 2022	SELL	$2.29 - $4.08 $916 - $1,632	-400 Reduced 5.88%	6,403 $15,000
Q2 2022 Aug 10, 2022	SELL	$2.39 - $4.93 $207 - $428	-87 Reduced 1.26%	6,803 $19,000
Q1 2022 May 04, 2022	BUY	$3.45 - $8.77 $13,948 - $35,457	4,043 Added 142.01%	6,890 $32,000
Q3 2021 Nov 05, 2021	SELL	$11.94 - $16.09 $129,059 - $173,916	-10,809 Reduced 79.15%	2,847 $36,000
Q2 2021 Aug 02, 2021	SELL	$14.36 - $20.93 $102,659 - $149,628	-7,149 Reduced 34.36%	13,656 $212,000
Q1 2021 May 13, 2021	BUY	$18.19 - $33.25 $42,673 - $78,004	2,346 Added 12.71%	20,805 $421,000
Q4 2020 Feb 10, 2021	SELL	$15.87 - $31.64 $11,680 - $23,287	-736 Reduced 3.83%	18,459 $500,000
Q3 2020 Nov 12, 2020	SELL	$15.7 - $20.84 $12,277 - $16,296	-782 Reduced 3.91%	19,195 $356,000
Q2 2020 Aug 14, 2020	SELL	$8.21 - $21.02 $311 - $798	-38 Reduced 0.19%	19,977 $355,000
Q1 2020 May 18, 2020	BUY	$7.81 - $18.82 $156,317 - $376,682	20,015 New	20,015 $184,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.